UTv Videos

"The wide variability that we found across MUSIC practices suggests an opportunity for us for quality improvement initiatives and additional evidence surrounding who should receive secondary treatment and what modalities," says Daniel A. Triner, MD, PhD.

"I think right now, a lot of the focus is on perioperative management, as well as some of the technical considerations of the surgery itself," says Jay Simhan, MD, FACS.

"We found that approximately 2 out of every 3 patients with node-positive disease go on to some form of secondary treatment within 12 months," says Daniel A. Triner, MD, PhD.

"We're doing a lot of active surveillance, and it's good to know that most of these people are getting the appropriate care that they should receive," says Yuzhi (Katherine) Wang, MD.

“Also, the technique lends itself really nicely to these, what we call posterior ball-valve tumors, which are these tumors that sit behind the renal hilum, behind the blood vessels on the posterior side of the kidney,” says Alexander Kutikov, MD, FACS.

“All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick Soon-Shiong, MD.

"There's definitely more work to do to confirm these results on a multi-institutional aspect," says Ryan L. Steinberg, MD.

In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.

"We've developed the Get Moving Trial, which is a randomized controlled phase 1/2 trial to demonstrate the safety, feasibility and efficacy of a home-based pre-op program that is personalized," says Sarah P. Psutka, MD, MSc.

"So, in the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every 3 months for up to 1 year, compared to intravesical chemotherapy," says Roger Li, MD.

Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.

Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the 2024 AUA Annual Meeting.

"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.

“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W. Dunn, MSN, NP-C, OCN, RN.

Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.

Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."

Neal D. Shore, MD, shares what he's most looking forward to at this year's American Urological Association Annual Meeting.

"Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel as compared to BCG," says Ryan L. Steinberg, MD.

“There is great interest in looking at all these targeted interventions in the earlier stages to lower the burden of care that patients go through and to some degree that urologists and other health care professionals in this in this realm go through,” says Surena F. Matin, MD.

“It's a system that is still not being used to its maximum capability, which is exciting. That means we can continue evolving,” says Jaschar Shakuri-Rad, DO, FACOS.

“What we find here was that of the patients who had FGFR3 alterations, 67% of them had tumors that responded,” says Surena F. Matin, MD.

Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.

"Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH," says Eiftu S. Haile, MD.

In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.

"Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate," says Eiftu S. Haile, MD.

“I cannot overstate the impact of this device on my management of kidney stone patients," says J. Stuart Wolf, Jr., MD, FACS.

"Prostate radiotherapy is obviously widely available, inexpensive, generally [with] a mild toxicity profile. So I think it's a reasonable option in that scenario in patients who present with de novo low-volume disease," says , Scott Morgan, MD, MSc, FRCPC.